AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
49.7%
132M of 266M shares
Institutional holders
84
10 new, 10 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $15.71K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kaufman Michael A | 33,621,487 | 12.60% | 13G (passive) amendment | Mar 31, 2026 |
| MAK Capital One L.L.C. | 30,005,343 | 11.30% | 13G (passive) amendment | Dec 31, 2025 |
| Kenneth Galbraith | 28,821,053 | 10.80% | 13G (passive) amendment | Mar 31, 2025 |
| Wellington Investment Advisors Holdings LLP | 27,091,700 | 10.20% | 13G (passive) amendment | Mar 31, 2025 |
| Michael A. Kaufman | 26,887,508 | 10.10% | 13G (passive) amendment | Dec 1, 2025 |
| Steven Boyd | 15,600,000 | 5.86% | 13G (passive) | Sep 30, 2025 |
| Armistice Capital, LLC | 15,000,000 | 5.64% | 13G (passive) amendment | Jun 30, 2026 |
| PPF Group a.s. | 14,782,275 | 5.60% | 13D (active) amendment | Aug 27, 2026 |
| Ppf Biotech B.V. | 14,612,275 | 5.50% | 13D (active) amendment | Mar 21, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AUTL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mak Capital One LLC | 33,621,487 | 12.63% | $53.79M | – | 7.54% |
| Blackstone Inc. | 20,485,611 | 7.70% | $32.78M | – | 0.10% |
| Syncona Portfolio Ltd | 16,640,720 | 6.25% | $26.63M | – | 100.00% |
| Armistice Capital, LLC | 15,000,000 | 5.64% | $24.00M | −800,000 | 0.29% |
| TFG Asset Management GP Ltd | 9,500,000 | 3.57% | $15.20M | – | 2.39% |
| Schroder Investment Management Group | 7,833,282 | 2.94% | $12.92M | −1,656,063 | 0.01% |
| Frazier Life Sciences Management, L.P. | 4,447,910 | 1.67% | $7.12M | – | 0.15% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | 1.26% | $5.38M | – | 0.01% |
| Laurion Capital Management LP | 3,316,626 | 1.25% | $5.31M | – | 0.14% |
| Renaissance Technologies LLC | 1,984,700 | 0.75% | $3.18M | −314,799 | 0.00% |
| Bank Of America Corp /De/ | 1,605,092 | 0.60% | $2.57M | −239,579 | 0.00% |
| BlackRock, Inc. | 1,603,458 | 0.60% | $2.57M | +122,726 | 0.00% |
| UBS Group AG | 1,516,991 | 0.57% | $2.43M | +211,212 | 0.00% |
| Morgan Stanley | 1,260,832 | 0.47% | $2.02M | +319,009 | 0.00% |
| Millennium Management LLC | 1,224,818 | 0.46% | $1.96M | +1,020,090 | 0.00% |
| Cetera Investment Advisers | 1,157,324 | 0.43% | $1.85M | +28,250 | 0.00% |
| Balyasny Asset Management L.P. | 972,748 | 0.37% | $1.56M | +1,057 | 0.00% |
| JPMorgan Chase & Co | 913,239 | 0.34% | $1.51M | −22,164 | 0.00% |
| Alphabet Inc. | 698,262 | 0.26% | $1.12M | – | 0.00% |
| Citadel Advisors LLC | 695,890 | 0.26% | $1.11M | +236,486 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 84 | 132M | 49.7% | 10 / 28 | 21 / 10 | 3M | 5M |
| Q1 2026 | 84 | 134M | 50.5% | 9 / 22 | 30 / 13 | 6M | 11M |
| Q4 2025 | 89 | 139M | 52.4% | 14 / 25 | 29 / 19 | 13M | 16M |
| Q3 2025 | 96 | 146M | 54.7% | 14 / 35 | 23 / 12 | 38M | 58M |
| Q2 2025 | 94 | 166M | 62.4% | 19 / 33 | 26 / 20 | 24M | 26M |
| Q1 2025 | 95 | 168M | 63.2% | 8 / 30 | 33 / 23 | 13M | 14M |
| Q4 2024 | 110 | 168M | 63.3% | 23 / 34 | 31 / 14 | 13M | 24M |
| Q3 2024 | 101 | 180M | 67.6% | 7 / 31 | 36 / 16 | 20M | 14M |
| Q2 2024 | 111 | 179M | 67.1% | 15 / 39 | 31 / 24 | 29M | 27M |
| Q1 2024 | 120 | 177M | 66.6% | 27 / 46 | 27 / 6 | 71M | 9M |
| Q4 2023 | 99 | 116M | 43.6% | 34 / 21 | 19 / 5 | 20M | 15M |
| Q3 2023 | 71 | 111M | 41.6% | 10 / 14 | 25 / 8 | 8M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AUTL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 1,428,929 | 0.54% | $2.29M | 0.03% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 120,878 | 0.05% | $226.04K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 84,409 | 0.03% | $135.05K | 0.02% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 44,936 | 0.02% | $84.03K | 0.44% | May 31, 2026 |
| ActivePassive International Equity ETF | 22,753 | 0.01% | $42.55K | 0.00% | May 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 10,575 | 0.00% | $19.78K | 0.03% | May 31, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 7,414 | 0.00% | $13.86K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -14,000 | -0.01% | -$22.40K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christian Itin | Chief Executive Officer, Director | 1,116,009 | 0.42% | Mar 18, 2026 |
| Cintia Piccina | U.S. CCO & Country Gen Manager | 13,287 | 0.00% | Sep 3, 2026 |
| Christopher Andrew Vann | Chief Operating Officer | 152,211 | 0.06% | Mar 18, 2026 |
| Alexander Swan | Chief Human Resources Officer | – | – | Mar 18, 2026 |
| Alex Driggs | SVP, Legal Affairs and GC | – | – | Mar 18, 2026 |
| Miranda Suzette Neville | Chief Technology Officer | – | – | Mar 18, 2026 |
| Robert Dolski | Chief Financial Officer | – | – | Mar 18, 2026 |
| Patrick Paul McIlvenny | SVP Finance | – | – | Mar 18, 2026 |
| Christopher Michael James Williams | Chief Business Officer | 8,198 | 0.00% | Mar 18, 2026 |
| Matthias Will | Chief Development Officer | – | – | Mar 18, 2026 |
| Linda Bain | Director | – | – | Jul 1, 2026 |
| Cynthia M. Butitta | Director | – | – | Jul 1, 2026 |
| Ryan Richardson | Director | – | – | Jul 1, 2026 |
| Robert Azelby | Director | – | – | Jul 1, 2026 |
| Robert Iannone | Director | – | – | Jul 1, 2026 |
| Elisabeth Leiderman | Director | – | – | Jul 1, 2026 |
| Michael W. Bonney | Director | – | – | Jul 1, 2026 |
| Madduri Ravin Rao | Director | – | – | Jul 1, 2026 |
| William D. Young | Director | – | – | Jul 1, 2026 |
| John E. Berriman | Director | 136,331 | 0.05% | Mar 18, 2026 |
| Martin Anton Pule | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cintia Piccina U.S. CCO & Country Gen Manager | Sep 2, 2026 | Sale | −6,713 | $2.34 | $15.71K | 13,287 |
| Cintia Piccina U.S. CCO & Country Gen Manager | Sep 1, 2026 | Option exercise | +20,000 | $2.35 | $47.00K | 20,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cintia Piccina Officer | Sep 2, 2026 | 6,713 | $15.68K | Sep 2, 2026 | Restricted Stock Vesting |
| Pule Martin Officer | Sep 16, 2024 | 698,741 | $2.96M | Sep 16, 2024 | Shares were issued on foundation of the company and converted from private to public shares at IPO |